1. Давыдов М.И., Полоцкий Б.Е. Рак легкого. М.: Радикс, 1994.
2. Трахтенберг А.Х., Чиссов В.И. Клиническая онкопульмонология. М.: ГЭОТАР-Медиа, 2000.
3. The health consequences of smoking: a report of the Surgeon General. Available at: https://www.hhs.gov/surgeongeneral/reports-and-publications/tobacco/consequences-smoking-factsheet/index.html.
4. Состояние онкологической помощи населению России в 2019 году / под ред. А.Д. Каприна, В.В. Старинского,. А.О. Шахзадовой – М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020. − илл. – 239 с. ISBN 978-5-85502-255-1 Доступно по: http://www.oncology.ru/service/statistics/condition/2019.pdf. Доступно по: http://www.oncology.ru/service/statistics/condition/2017.pdf.
5. Stahel R., Peters S., Garassino M. Thoracic tumours essentials for clinicians. ESMO Press, 2014.
6. WHO classification of tumours of the lung, pleura, thymus and heart 2015.
7. The AJCC Cancer staging manual. Eight ed. Springer, 2017.
8. Grunnet M., Sorensen J.B., Carcinoembrionic antigen (CEA) as a tumor marker in lung cancer. Lung Cancer 2012;76:138–43.
9. Planchard D., Popat S., Kerr R. et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann of Oncology 2018;29(Suppl. 4):192–234.
10. NCCN Guidelines. Non-small cell lung cancer, version 7.2019. Available at: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
11. Travis D.W., Brambilla E., Burke A.P. et al. Classification of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press, 2015.
12. Lung cancer. Ed. by F.V. Fossella, J.B. Putnam, R. Komaki. NewYork: Springer, 2003.
13. Schrump D.S., Carter D., Kelsey C.R. et al. Non-small cell lung cancer. In: DeVita, Hellman, and Rosenberg cancer; prinsiples and practice of oncology. Ed. by V.T. DeVita Jr, T.S. Lawrence, S.A. Rosenberg et al. Philadelphia: Lippincott Williams and Wilkins, 2011.
14. Трахтенберг А.Х., Чиссов В.И., Франк Г.А. Нейроэндокринные опухоли легких. М.: Практическая медицина, 2012.
15. Аллахвердиев А.К., Давыдов М.М. Торакоскопическая лобэктомия с медиастинальной лимфодиссекцией стандарт в хирургическом лечении больных немелкоклеточным раком легкого Т1–2N0М0. Вопросы онкологии 2015;61(3):413–7.
16. Higuchi M., Yaginuma H., Yonechi A. et al. Long-term outcomes after video-assisted thoracic surgery (VATS) lobectomy versus lobectomy via open thoracotomy for clinical stage Ia non-small cell lung cancer. J Cardiothorac Surg 2014;9:88–92.
17. Lindberg K., Nyman J., Riesenfeld Kallskog V. et al. Long-term of a results of prospective trial phase II of medically inoperable stage I NSCLC treated with SBRT – the Nordic experience. Acta Oncol 2015;54:1096–104.
18. Zhang T., Guo Q., Zhang Y. et al. Meta-analysis of adjuvant chemotherapy versus surgery alone in T2aN0 stage IB non-small cell lung cancer. J Can Res Ther 2018;14:139–44.
19. Winton T., Livingston R., Johnson D. et al. Vinorelbine plus cisplatinvs observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589–97.
20. Arriagada R., Dunant A., Pignon J.P. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol. 2010;28(1):35–42. doi: 10.1200/JCO.2009.23.2272.
21. NSCLC Meta-analyses Collaborative Group. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 2010;375(9722):1267–77.
22. Aureperin A., Le Pechoux C., Rolland E. et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small cell lung cancer. J Clin Oncol 2010;28:2181–90.
23. Tsitsias T., Boulemden A., Ang K. et al. The N2 paradox: similar outcomes of pre- and postoperatively identified single-zone N2a positive non-small-cell lung cancer. J Eur Cardiothorac Surg 2014;45:882–7.
24. Scagliotti G.V., Pastorino U., Vansteenkiste J.F. et al. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. J Clin Oncol 2012;30:172–8.
25. Usami N., Yokoi K., Hasegawa Y. et al. Phase II study of carboplatin and gemcitabine as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial. Int J Clin Oncol 2010;15:583–7.
26. Pérol M., Chouaid C., Pérol D. et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2012;30:3516–24.
27. Gilligan D., Nicolson M., Smith I. et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT2/EORTC 08012 multicentre randomised trial and update of systematic review. The Lancet 2007;369(9577):1929–37. doi: 10.1016/S0140-6736(07)60714-4.
28. Strauss G.M., Herndon III J.E., Maddaus M.A. et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008;26:5043–51.
29. Fossella F., Pereira J.R., von Pawel J. et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003;21:3016–24.